New cell therapy aims to stop transplant complications in blood cancer patients

NCT ID NCT04328714

First seen Nov 01, 2025 · Last updated Jun 02, 2026 · Updated 31 times

Summary

This early-phase study tested whether a special type of cell (interferon gamma-primed mesenchymal stromal cells) could be safely given to prevent graft-versus-host disease, a common and serious complication after bone marrow transplant. Only 4 patients with acute leukemia or myelodysplastic syndrome were enrolled before the study was stopped. The main goals were to see if the cells could be prepared and delivered safely, and to find the best dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Children's Healthcare of Atlanta at Egleston

    Atlanta, Georgia, 30322, United States

  • Emory University

    Atlanta, Georgia, 30322, United States

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia, 30322, United States

Conditions

Explore the condition pages connected to this study.